ArticleTranslational cancer research2020
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: a case report and literature review.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: case series and systematic review.Neuroradiology · 2024Pooled it
- A case report of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with literature review.Frontiers in oncology · 2026Article
- Clinicopathologic characteristics of low-grade thyroid-like nasopharyngeal papillary adenocarcinoma: a case report.International journal of clinical and experimental pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-LGNPPA) is a rare disease, and consensus regarding the diagnosis, clinical management, and prognosis for this population is lacking. This study aimed to assess the immunohistochemical features, clinical management, and prognosis of TL-LGNPPA through a comprehensive literature review. We reported a patient diagnosed with TL-LGNPPA in our institution. In addition, we reviewed the published literature from PubMed, Science Direct, Web of Science, Google Scholar, and China National Knowledge Internet to synthetically review the patient characteristics, treatments, and outcomes for TL-LGNPPA. We included 46 patients in this study, and most of them (76.1%) came from Asia. The most common symptoms were nasal obstruction, epistaxis, and bloody sputum. The tumors mainly occurred in the posterior roof of the nasopharynx or nasal septum. In patients with available immunohistochemical results, all patients were overexpression of thyroid transcription factor 1 (100%), CK7 (100%), CK19 (100%), Ckpan (100%), and epithelial membrane antigen (100%). In addition, the majority of them were Vimentin overexpression (94.7%). However, TL-LGNPPA patients were more likely to have lower-expression of CK20 (100%), smooth muscle actin (100%), Epstein-Barr virus-encoded RNA (100%), thyroglobulin (97.8%), CK5/6 (92.6%), S-100 (86.7%), and P63 (85.8%). All of the patients underwent surgery, and two of them received postoperative radiotherapy. With a median follow-up time of 16 months, and 16% of them were follow-up for more than five years, no locoregional recurrences or distant metastasizes occurred. In conclusion, TL-LGNPPA is an extremely rare entity with unique disease features and excellent prognosis. Surgery is the optimal treatment for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.